BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cózar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-Infiltrating Natural Killer Cells. Cancer Discov 2021;11:34-44. [PMID: 33277307 DOI: 10.1158/2159-8290.CD-20-0655] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Reference Citation Analysis]
2 Hu Z, Xu X, Wei H. The Adverse Impact of Tumor Microenvironment on NK-Cell. Front Immunol 2021;12:633361. [PMID: 34177887 DOI: 10.3389/fimmu.2021.633361] [Reference Citation Analysis]
3 Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J Immunother Cancer 2021;9:e002873. [PMID: 34645669 DOI: 10.1136/jitc-2021-002873] [Reference Citation Analysis]
4 Zeng R, Huang S, Qiu X, Zhuo Z, Wu H, Jiang L, Sha W, Chen H. Predicting the Prognosis of Esophageal Adenocarcinoma by a Pyroptosis-Related Gene Signature. Front Pharmacol 2021;12:767187. [PMID: 34867395 DOI: 10.3389/fphar.2021.767187] [Reference Citation Analysis]
5 Khawar MB, Sun H. CAR-NK Cells: From Natural Basis to Design for Kill. Front Immunol 2021;12:707542. [PMID: 34970253 DOI: 10.3389/fimmu.2021.707542] [Reference Citation Analysis]
6 Lee EHC, Wong DCP, Ding JL. NK Cells in a Tug-of-War With Cancer: The Roles of Transcription Factors and Cytoskeleton. Front Immunol 2021;12:734551. [PMID: 34594338 DOI: 10.3389/fimmu.2021.734551] [Reference Citation Analysis]
7 Zhang P, He B, Cai Q, Tu G, Peng X, Zhao Z, Peng W, Yu F, Wang M, Tao Y, Wang X. Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity. Front Oncol 2021;11:705888. [PMID: 34568032 DOI: 10.3389/fonc.2021.705888] [Reference Citation Analysis]
8 Palano MT, Gallazzi M, Cucchiara M, De Lerma Barbaro A, Gallo D, Bassani B, Bruno A, Mortara L. Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis. Vaccines (Basel) 2021;9:1488. [PMID: 34960234 DOI: 10.3390/vaccines9121488] [Reference Citation Analysis]
9 Zhang C, Hu Y, Xiao W, Tian Z. Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy. Cell Mol Immunol 2021. [PMID: 34267335 DOI: 10.1038/s41423-021-00732-6] [Reference Citation Analysis]
10 Tata A, Dodard G, Fugère C, Leget C, Ors M, Rossi B, Vivier E, Brossay L. Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers. Oncoimmunology 2021;10:1933808. [PMID: 34188973 DOI: 10.1080/2162402X.2021.1933808] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zhang Z, Su J, Li L, Du W. Identification of Precise Therapeutic Targets and Characteristic Prognostic Genes Based on Immune Gene Characteristics in Uveal Melanoma. Front Cell Dev Biol 2021;9:666462. [PMID: 34124047 DOI: 10.3389/fcell.2021.666462] [Reference Citation Analysis]
12 Yang B, Chen Q. Cross-Talk between Oxidative Stress and m6A RNA Methylation in Cancer. Oxid Med Cell Longev 2021;2021:6545728. [PMID: 34484567 DOI: 10.1155/2021/6545728] [Reference Citation Analysis]
13 Sierra JM, Secchiari F, Nuñez SY, Iraolagoitia XLR, Ziblat A, Friedrich AD, Regge MV, Santilli MC, Torres NI, Gantov M, Trotta A, Ameri C, Vitagliano G, Pita HR, Rico L, Rovegno A, Richards N, Domaica CI, Zwirner NW, Fuertes MB. Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation. Front Immunol 2021;12:745939. [PMID: 34616407 DOI: 10.3389/fimmu.2021.745939] [Reference Citation Analysis]
14 Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets 2021;25:835-45. [PMID: 34806500 DOI: 10.1080/14728222.2021.2010046] [Reference Citation Analysis]
15 Liu Y, Zhou X, Wang X. Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol 2021;14:125. [PMID: 34404434 DOI: 10.1186/s13045-021-01134-x] [Reference Citation Analysis]
16 Yu Z, Song Y, Cai M, Jiang B, Zhang Z, Wang L, Jiang Y, Zou L, Liu X, Yu N, Mao X, Peng C, Liu S. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Aging (Albany NY) 2021;13:21294-308. [PMID: 34470916 DOI: 10.18632/aging.203459] [Reference Citation Analysis]
17 Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol 2021;9:750022. [PMID: 34858978 DOI: 10.3389/fcell.2021.750022] [Reference Citation Analysis]
18 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Reference Citation Analysis]
19 Fisher JG, Walker CJ, Doyle AD, Johnson PW, Forconi F, Cragg MS, Landesman Y, Khakoo SI, Blunt MD. Selinexor Enhances NK Cell Activation Against Malignant B Cells via Downregulation of HLA-E. Front Oncol 2021;11:785635. [PMID: 34926302 DOI: 10.3389/fonc.2021.785635] [Reference Citation Analysis]
20 Niu X, Chen L, Li Y, Hu Z, He F. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.03.009] [Reference Citation Analysis]
21 Afolabi LO, Afolabi MO, Sani MM, Okunowo WO, Yan D, Chen L, Zhang Y, Wan X. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. Clin Transl Immunology 2021;10:e1286. [PMID: 34188916 DOI: 10.1002/cti2.1286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yu W, Lei Q, Yang L, Qin G, Liu S, Wang D, Ping Y, Zhang Y. Contradictory roles of lipid metabolism in immune response within the tumor microenvironment. J Hematol Oncol 2021;14:187. [PMID: 34742349 DOI: 10.1186/s13045-021-01200-4] [Reference Citation Analysis]
23 Lenci E, Marcantognini G, Cognigni V, Lupi A, Rinaldi S, Cantini L, Fiordoliva I, Carloni AL, Rocchi M, Zuccatosta L, Gasparini S, Berardi R. Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00043] [Reference Citation Analysis]
24 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
25 Schoutrop E, Moyano-Galceran L, Lheureux S, Mattsson J, Lehti K, Dahlstrand H, Magalhaes I. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment. Semin Cancer Biol 2022:S1044-579X(22)00083-9. [PMID: 35395389 DOI: 10.1016/j.semcancer.2022.03.027] [Reference Citation Analysis]
26 Pan C, Zhai Y, Li G, Jiang T, Zhang W. NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. Front Oncol 2021;11:751183. [PMID: 34765554 DOI: 10.3389/fonc.2021.751183] [Reference Citation Analysis]
27 Walle T, Kraske JA, Liao B, Lenoir B, Timke C, von Bohlen Und Halbach E, Tran F, Griebel P, Albrecht D, Ahmed A, Suarez-Carmona M, Jiménez-Sánchez A, Beikert T, Tietz-Dahlfuß A, Menevse AN, Schmidt G, Brom M, Pahl JHW, Antonopoulos W, Miller M, Perez RL, Bestvater F, Giese NA, Beckhove P, Rosenstiel P, Jäger D, Strobel O, Pe'er D, Halama N, Debus J, Cerwenka A, Huber PE. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv 2022;8:eabh4050. [PMID: 35319989 DOI: 10.1126/sciadv.abh4050] [Reference Citation Analysis]
28 Braud VM, Meghraoui-kheddar A, Elaldi R, Petti L, Germain C, Anjuère F. LLT1-CD161 Interaction in Cancer: Promises and Challenges. Front Immunol 2022;13:847576. [DOI: 10.3389/fimmu.2022.847576] [Reference Citation Analysis]
29 Wei Z, Yi Y, Luo Z, Gong X, Jiang Y, Hou D, Zhang L, Liu Z, Wang M, Wang J, Guo R, Yang J, Wang L, Wang H, Zhao Y. Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy. Adv Mater 2022;:e2108167. [PMID: 35132688 DOI: 10.1002/adma.202108167] [Reference Citation Analysis]
30 Capuano C, Pighi C, Battella S, De Federicis D, Galandrini R, Palmieri G. Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs. Cancers (Basel) 2021;13:2500. [PMID: 34065399 DOI: 10.3390/cancers13102500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Jegatheeswaran S, Mathews JA, Crome SQ. Searching for the Elusive Regulatory Innate Lymphoid Cell. J Immunol 2021;207:1949-57. [PMID: 34607908 DOI: 10.4049/jimmunol.2100661] [Reference Citation Analysis]
32 Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2021. [PMID: 34937915 DOI: 10.1038/s41573-021-00345-8] [Reference Citation Analysis]